Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years or legal age of majority depending on regional law~* Fasting, calculated LDL-C at screening ≥160 mg/dL and following PCSK9i therapy ≥70 mg/dL~* Men and nonpregnant, nonlactating women~Exclusion Criteria:~* Heterozygous (HeFH) or Homozygous (HoFH) Familial Hypercholesterolemia~* Total fasting TG ≥500 mg/dL~* Renal dysfunction or a glomerulonephropathy; eGFR \<30 mL/min/1.73 m2~* Known cardiovascular disease (CVD), peripheral arterial disease (PAD), or cerebrovascular disease (CD)~* History of type 1 or type 2 diabetes~* Uncontrolled hypertension~* Uncontrolled hypothyroidism~* Liver disease or dysfunction~* Gastrointestinal conditions or procedures (including Lap-Band® or gastric bypass)~* History of hematologic or coagulation disorders~* History of malignancy (except non-metastatic basal or squamous cell carcinoma of the skin and cervical carcinoma in situ)~* Unexplained creatine kinase (CK) \>3 × ULN~* Use of a cholesterylester transfer protein (CETP) inhibitor in the last 12 months prior to screening, such as: anacetrapib, dalcetrapib, or evacetrapib~* Pregnant or breast feeding, or planning to become pregnant during treatment and/ or within 30 days after the end of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bempedoic acid (Type: EXPERIMENTAL): Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
- placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly

Based on this trial design, predict the completion outcome and termination type (if applicable).